U.S. FDA Head Faces Grilling Over China’s Heparin
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA Commissioner Andrew C. von Eschenbach faced a tough line of questioning from members of the House Energy & Commerce Subcommittee on Oversight and Investigations during an April 22 hearing on the agency's foreign drug inspection program
You may also be interested in...
U.S. FDA Pinpoints Culprit In Bad Heparin
U.S. FDA has evaluated data that provides "a very solid mechanistic link" between patients who have received bolus dosing of contaminated heparin and observed adverse reactions, according to Center for Drug Evaluation and Research Director Janet Woodcock
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).